Bear Stearns keeps MedImmune at outperform

MedImmune Inc. was maintained at outperform with a $35 price target by Bear Stearns analyst Mark Schoenebaum. The American Academy of Pediatricians recently released its 2006 Red Book outlining pediatric infectious diseases and recommends guidelines for treatment and/or prevention. The analyst is not changing its model, expecting U.S. Synagis growth of 1% in 2006 and 5% in 2007. Shares of the Gaithersburg, Md.-based biotechnology company were down 29 cents, or 0.96%, at $29.78 on volume of 2,838,039 shares versus the three-month running average of 2,410,050 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.